ReviewMikrochimica acta2025
miRNA biomarkers: advancing early detection of acute myocardial infarction.
Review in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and Validation of a SHAP-Interpretable Machine Learning Model for Stroke Risk Prediction Using Circulating MicroRNA Biomarkers.Journal of molecular neuroscience : MN · 2026Article
- LDAR outperforms other albumin-derived indices in predicting 28-day ICU mortality in critically ill myocardial infarction patients: a two-cohort study.Frontiers in medicine · 2026Article
- Deciphering the clinical implication of an obesity-related gene signature as the novel biomarker for acute myocardial infarction diagnosis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Acute myocardial infarction (AMI) is the most serious cardiovascular disease with high morbidity and mortality worldwide, characterized by myocardial necrosis due to acute or persistent ischemia and hypoxia of cardiac muscle. Early diagnosis and timely treatment of AMI can significantly mitigate mortality rates and disability. Currently, troponin is the primary diagnostic marker for clinical detection of AMI. However, a discernible abnormal elevation of troponin is not detectable until 3-4 h after the onset of AMI. Hence, it is urgent to develop more sensitive biomarkers capable of predicting early indications. MicroRNAs hold great potential as novel markers in the early diagnosis of AMI due to their early appearance and specificity. Research has demonstrated that certain microRNAs can be detected within 1 h following the onset of acute myocardial infarction. To facilitate early differentiation of AMI progression, numerous state-of-the-art techniques have been developed for efficient detection of AMI-derived microRNAs. This review provides an in-depth examination of the diverse potential microRNA markers along with their detection methodologies over the past eight years, emphasizing the technical advantages, limitations, and future prospects.
Indexed as
Identifiers
40650826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.